Episurf Medical announces that trading with paid-up shares will end on 1 July 2019

Last trading day for paid-up shares

Episurf Medical AB’s (publ) (”Episurf Medical”) rights issue that raised SEK 75.2m before deduction of issue related costs has been registered with the Swedish Companies Registration Office. Trading in paid-up shares created in Episurf Medical AB's (publ) rights issue in May 2019 will end on 1 July 2019 and the stop day will be 3 July 2019.

478,147 new shares of series A and 53,251,966 new shares of series B have been registered with the Swedish Companies Registration Office. The shares are expected to be delivered to the shareholders’ by 5 July 2019.

Advisors 

Redeye AB is financial advisors and DLA Piper Sweden is legal advisor to Episurf Medical in the rights issue.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

The information was submitted for publication, through the agency of the contact person set out above, at 10.30 CEST on 28 June 2019.

Tags: